Better Health for All

Genenta Science is a clinical-stage biotechnology company entirely focused on developing gene therapies for cancer, with its lead product candidate, Temferon, showing promising results.

In the TEM-GBM study for glioblastoma multiforme (GBM), 44% of patients reached 18-month survival, and the two-year survival rate is 29%, compared to historical standard of care rates of 14% for two-year survival and 13–15 months median overall survival. The company has completed a Phase 1 trial for GBM and initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma. Genenta has no revenue from harmful products. The company held approximately $30 million in cash and short-term investments as of November 1, 2025, and secured €20 million ($21.9 million) in financing to advance its pipeline, demonstrating significant investment in health innovation. However, the company explicitly states that Temferon is an investigational product, its effectiveness and safety have not been established, and clinical trial data is preliminary and subject to adjustment, indicating a lack of established safety and efficacy data.

Fair Pay & Worker Respect

No relevant data was found in the provided articles to assess Genenta Science S.p.A. against the 'Fair Pay & Worker Respect' ethical value. The articles either explicitly state that no data was found for the company

or are not relevant to Genenta Science S.p.A.

Honest & Fair Business

Genenta has implemented a whistleblowing channel that ensures confidentiality and prohibits retaliation, in compliance with Italian Legislative Decree no. 24/2023 and GDPR.

However, the evidence does not provide details on independent investigation processes, training, or the policy's communication to all staff.

Kind to Animals

No specific information relevant to Genenta Science S.p.A. (GNTA.US) and the 'Kind to Animals' value was found in the provided articles. The articles discuss general FDA policies

, industry trends, and actions by other companies , but do not contain any specific data points, policies, or actions attributable to GNTA.US regarding animal welfare, testing, or sourcing practices.

No War, No Weapons

Genenta Science S.p.A. is undergoing a strategic transformation, planning to change its name to Saentra Forge S.p.A.

and shift its focus from cell-based gene therapies to becoming a defense and national security-focused industrial consolidator. The company has invested in A.T.C. S.r.l., a manufacturer of high-precision tactical rifles and special-forces weapon systems, acquiring 19.5% equity ownership with an opportunity to acquire up to 51%. A.T.C. is authorized by the Italian Ministry of Defense and holds NATO qualifications. The Praexidia Foundation, which includes senior figures from the defense industry and armed forces, has become a strategic long-term shareholder and adds a consultative layer for transactions under Golden Power scrutiny. The company states it has not executed and does not contemplate executing exports or transactions in violation of Law No. 185/1990 or other export control laws, including restrictions concerning countries involved in armed conflict. A put option allows Genenta to exit A.T.C. if licenses are suspended for at least two months or if A.T.C. underperforms against defined thresholds.

Planet-Friendly Business

The company has a target to achieve true zero emissions by 2050.

No specific regulatory actions, violations, fines, or compliance issues were mentioned in the provided information.

Safe & Smart Tech

For whistleblowing reports, personal data is retained for a period not exceeding 5 years from the date of the communication of the result of the reporting process to the whistleblower.

The company complies with Reg. (UE) 2016/679 (GDPR) and Legislative Decree no. 24/2023 (Whistleblowing Decree). Data subjects have rights to access, rectification, cancellation, and limitation of processing under Article 15 of the GDPR. Whistleblowers are asked not to enter irrelevant information, and data is deleted when unnecessary. There are no documented incidents of unauthorized data use.